Glial Cell Tumors
Conditions
Keywords
Glial Cell Tumors, Progastrin, hPG80
Brief summary
PROGLIO is a French mono-centric study with longitudinal follow-up, in which patients with high grade brain tumors will be included. Blood samples will be taken during their therapeutic follow-up to evaluate plasma concentrations of hPG80 (circulating progastrin).
Interventions
BIOLOGICALBlood sample
Evaluation of plasma hPG80 concentrations by fasting blood samples. A total of seven 5 mL blood samples will be taken: Before radiation therapy; at the end of radiation therapy; at cycle 3 of chemotherapy; at cycle 6 of chemotherapy; 3 months after the end of treatment; 6 months after the end of treatment; and 9 months after the end of treatment.
Sponsors
ECS Progastrin
Centre Jean Perrin
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Female or male 18 years of age or older. * Patients with a high grade primary glial tumor (Astrocytoma grade 3; Glioblastoma; Anaplastic Oligodendroglioma) * Patients scheduled to begin radiation and/or chemotherapy. * Able to give informed consent to participate in the research. * Enrolled in a social security plan or beneficiary of such a plan.
Exclusion criteria
* Patient under guardianship or curatorship * Psychological disorder (cognitive disorders, vigilance disorders, etc.) or social reasons (deprivation of liberty by judicial or administrative decision) or geographical reasons that could compromise the medical follow-up of the trial. * Refusal to participate. * Pregnant or breastfeeding woman.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Plasma concentrations of hPG80 | From Radiotherapy 1st session to 9 month follow-up | To evaluate plasma concentrations of hPG80 (circulating progastrin) during therapeutic and recurrence follow-up in patients with high-grade brain tumors. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| hPG80 concentration according to tumor progression | Through study completion, an average of 1 year and 6 months | To study hPG80 concentration according to tumor progression in patients with high-grade brain tumor |
| Sensitivity of hPG80 concentration changes to irradiation | Through study completion, an average of 1 year and 6 months | To evaluate the sensitivity of hPG80 concentration changes to irradiation in patients with high-grade brain tumor. |
| Interindividual variations of hPG80 concentration | Through study completion, an average of 1 year and 6 months | To compare the plasma expression level of hPG80 in patients with high-grade brain tumor to study interindividual variations around and during disease management. |
Countries
France
Outcome results
None listed